WAY was assigned the co-organization of the Press Conference for the launch of the product Aptima mRNA HPV Test, the most advanced protection for women against cervical cancer, by the company AENORASIS, held on Thursday, 24 November 2016, at an upscale Athens hotel.
The presentation of the Aptima mRNA HPV Test involved the participation of distinguished Greek scientific experts. The Press Conference was addressed by
Mr. Evangelos Paraskevaidis, Professor of Obstetrics and Gynaecology at the Department of Medicine of the University of Ioannina, Chairman of the Hellenic Society for Colposcopy and Cervical Pathology, and Chairman of the HeCPA Study Group (Hellenic Cervical Pathology Academic Study Group), Ioannina, Mr. Petros Karakitsos, Professor of Cytology at the Department of Medicine of the National and Kapodistrian University of Athens, Chairman of the Hellenic Society of Clinical Cytology, and Director of the Diagnostic Cytology Laboratory of “Attikon” University Hospital, Athens, and Mr. Evripidis Bilirakis, Obstetrician-Gynaecologist, Doctor at the University of Ioannina, Secretary of the Hellenic Society for Colposcopy, and head of the colposcopy department of the 1st Clinic of the “Helena Venizelou” General and Maternity Hospital, Athens.
According to this group’s early research findings, the Aptima mRNA HPV Test, combined with the ThinPrep Pap Test, provides the safest prevention method for cervical cancer.
The Aptima mRNA HPV Test provides the most advanced development, combining Liquid Phase Cytology with the use of Molecular Biomarkers and thus contributing towards the maximum (almost 100%) protection of women from cervical cancer